BridgeBio Pharma (BBIO) Invested Capital (2018 - 2026)

BridgeBio Pharma (BBIO) posted Invested Capital of $547.5 million for Q1 2026, down 26.76% sequentially from $747.5 million in Q3 2021.

Analysis

BridgeBio Pharma (BBIO) Invested Capital (2018 - 2026) Analysis & Trends

BridgeBio Pharma has reported Invested Capital for 5 years, with the latest figure at $547.5 million in Q1 2026.

Quarterly Invested Capital changed N/A year-over-year to $547.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $547.5 million (changed N/A YoY) and the FY2020 annual result came in at $550.0 million, up 3316.15% from the prior year.
Invested Capital eased to $547.5 million in Q1 2026 per BBIO's latest filing, from $747.5 million in the prior quarter.
Over five years, Invested Capital peaked at $547.5 million in Q1 2026 and troughed at $547.5 million in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	33.70 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	7.35 Bn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	6.25 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	19.13 Bn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	1.30 Bn
10	BridgeBio Pharma	14.65 Bn	13.93 Bn	228.63 Mn	685.61 Mn

Historic Data

Download Data